jnj-42396302
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01732237)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Phosphodiesterase 10AINHIBITOR
PDE10A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1- Mol. weight
- 353.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2180408 ↗
Also known as
- jnj-42396302
- jnj-42396302
- jnj-42396302
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01732237 | Phase 1 | Aug 1, 2012 | Johnson and Johnson |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1